, Kyong-Min Kang2
, Mi Jeong Choi2
, Hye-Rim Shin2
, Tae-Gyun Lee3
, Hong-Min Ahn2
, Heung-Kwon Oh2
, Duck-Woo Kim2
, Sung-Bum Kang2
1Department of Surgery, Ewha Womans University College of Medicine, Seoul, Korea
2Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea
3Department of Surgery, Ajou University School of Medicine, Suwon, Korea
© 2026 The Korean Society of Coloproctology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflict of interest
Hong-Min Ahn is an editorial board member of this journal, but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflict of interest relevant to this article was reported.
Funding
This study was supported by the Seoul National University Bundang Hospital research fund (No. 14-2021-0030).
Acknowledgments
The authors gratefully acknowledge the contributions of the clinical research coordinators and nursing staff of the Department of Surgery at Seoul National University Bundang Hospital for their assistance in data collection and patient care.
Author contributions
Conceptualization: MHJ, SBK; Data curation: KMK, MJC, HRS, TGL, HMA, HKO, DWK; Formal analysis: MHJ, SBK; Funding acquisition: SBK; Investigation: KMK, MJC, HRS, TGL, HMA, HKO, DWK; Methodology: MHJ, SBK; Project administration: MHJ, SBK; Writing–original draft: MHJ, SBK; Writing–review & editing: all authors. All authors read and approved the final manuscript.
Additional information
This study was previously presented as an oral presentation at the 54th Congress of the Korean Society of Endo-Laparoscopic and Robotic Surgery (KSERS) and the 14th International Symposium on April 11–13, 2024, in Daejeon, Korea, and as an e-poster at the 2024 Annual Scientific Meeting of the American Society of Colon and Rectal Surgeons (ASCRS), on June 1–4, 2024, in Baltimore, MD, USA.
| Variable | Nontransverse colon cancer (n=1,151) | Transverse colon cancer (n=151) | P-value |
|---|---|---|---|
| T category | 0.331 | ||
| T1–T2 | 163 (14.2) | 17 (11.3) | |
| T3–T4 | 988 (85.8) | 134 (88.7) | |
| N category | 0.048 | ||
| N1 | 794 (69.0) | 116 (76.8) | |
| N2 | 357 (31.0) | 35 (23.2) | |
| No. of harvested lymph nodes | 42.3±20.5 | 56.0±28.2 | <0.001 |
| No. of metastatic lymph nodes | 3.4±4.0 | 2.8±3.2 | 0.070 |
| Proximal resection margin (cm) | 12.1±10.7 | 23.7±13.5 | <0.001 |
| Distal resection margin (cm) | 9.9±8.8 | 13.3±12.1 | 0.001 |
| Length of specimen (cm) | 21.8±15.5 | 36.8±15.3 | <0.001 |
| Lymphatic invasiona | 0.825 | ||
| No | 582 (50.7) | 78 (51.7) | |
| Yes | 566 (49.3) | 73 (48.3) | |
| Venous invasiona | 0.145 | ||
| No | 833 (72.6) | 118 (78.1) | |
| Yes | 315 (27.4) | 33 (21.9) | |
| Perineural invasiona | 0.340 | ||
| No | 487 (42.4) | 70 (46.7) | |
| Yes | 661 (57.6) | 80 (53.3) |
Values are presented as number (%) or mean±standard deviation.
aData on lymphatic, venous, and perineural invasion were unavailable for 3 patients in the nontransverse colon cancer group, and perineural invasion data were unavailable for 1 patient in the transverse colon cancer group, due to incomplete pathological records.
| Recurrence pattern | No. of patients (%) | P-value | |
|---|---|---|---|
| Nontransverse colon cancer (n=1,151) | Transverse colon cancer (n=151) | ||
| Locoregional recurrence | 23 (2.0) | 12 (7.9) | <0.001 |
| Near the anastomotic site | 12 (1.0) | 1 (0.7) | |
| Regional lymph nodes | 4 (0.3) | 10 (6.6) | |
| Peritoneal recurrence around the primary tumor | 7 (0.6) | 1 (0.7) | |
| Systemic recurrencea | 126 (10.9) | 19 (12.6) | 0.548 |
| Liver | 48 (4.2) | 8 (5.3) | |
| Lung | 48 (4.2) | 8 (5.3) | |
| Distant lymph nodes | 19 (1.7) | 4 (2.6) | |
| Multiple peritoneal seeding | 17 (1.5) | 1 (0.7) | |
| Otherb | 12 (1.0) | 3 (2.0) | |
Combined systemic and locoregional recurrence was detected in 8 patients in the nontransverse colon cancer group and in 4 patients in the transverse colon cancer group.
aPatients could have recurrence at more than one systemic site. bIncluding the ovaries, spleen, small bowel, adrenal gland, ureter, and bone.
| Characteristic | Nontransverse colon cancer (n=1,151) | Transverse colon cancer (n=151) | P-value |
|---|---|---|---|
| Age (yr) | 63.8±11.9 | 65.2±12.9 | 0.200 |
| ≤65 | 607 (52.7) | 73 (48.3) | 0.314 |
| >65 | 544 (47.3) | 78 (51.7) | |
| Sex | 0.332 | ||
| Male | 635 (55.2) | 77 (51.0) | |
| Female | 516 (44.8) | 74 (49.0) | |
| BMI (kg/m2) | 23.9±3.4 | 23.8±3.0 | 0.557 |
| ASA physical status | 0.280 | ||
| I | 336 (29.2) | 38 (25.2) | |
| II | 706 (61.3) | 95 (62.9) | |
| III | 105 (9.1) | 18 (11.9) | |
| IV | 4 (0.3) | 0 (0) | |
| Preoperative CEA (ng/mL) | 2.6 (1.5–5.9) | 2.1 (1.3–4.5) | 0.098 |
| Tumor location | - | - | |
| Ascending colon | 340 (29.5) | ||
| Descending colon | 68 (5.9) | ||
| Sigmoid colon | 743 (64.6) | ||
| 30-Day complication | 112 (9.7) | 22 (14.6) | 0.069 |
| Adjuvant chemotherapy | 1,048 (91.1) | 138 (91.4) | 0.917 |
| Variable | Nontransverse colon cancer (n=1,151) | Transverse colon cancer (n=151) | P-value |
|---|---|---|---|
| T category | 0.331 | ||
| T1–T2 | 163 (14.2) | 17 (11.3) | |
| T3–T4 | 988 (85.8) | 134 (88.7) | |
| N category | 0.048 | ||
| N1 | 794 (69.0) | 116 (76.8) | |
| N2 | 357 (31.0) | 35 (23.2) | |
| No. of harvested lymph nodes | 42.3±20.5 | 56.0±28.2 | <0.001 |
| No. of metastatic lymph nodes | 3.4±4.0 | 2.8±3.2 | 0.070 |
| Proximal resection margin (cm) | 12.1±10.7 | 23.7±13.5 | <0.001 |
| Distal resection margin (cm) | 9.9±8.8 | 13.3±12.1 | 0.001 |
| Length of specimen (cm) | 21.8±15.5 | 36.8±15.3 | <0.001 |
| Lymphatic invasion |
0.825 | ||
| No | 582 (50.7) | 78 (51.7) | |
| Yes | 566 (49.3) | 73 (48.3) | |
| Venous invasion |
0.145 | ||
| No | 833 (72.6) | 118 (78.1) | |
| Yes | 315 (27.4) | 33 (21.9) | |
| Perineural invasion |
0.340 | ||
| No | 487 (42.4) | 70 (46.7) | |
| Yes | 661 (57.6) | 80 (53.3) |
| Recurrence pattern | No. of patients (%) | P-value | |
|---|---|---|---|
| Nontransverse colon cancer (n=1,151) | Transverse colon cancer (n=151) | ||
| Locoregional recurrence | 23 (2.0) | 12 (7.9) | <0.001 |
| Near the anastomotic site | 12 (1.0) | 1 (0.7) | |
| Regional lymph nodes | 4 (0.3) | 10 (6.6) | |
| Peritoneal recurrence around the primary tumor | 7 (0.6) | 1 (0.7) | |
| Systemic recurrence |
126 (10.9) | 19 (12.6) | 0.548 |
| Liver | 48 (4.2) | 8 (5.3) | |
| Lung | 48 (4.2) | 8 (5.3) | |
| Distant lymph nodes | 19 (1.7) | 4 (2.6) | |
| Multiple peritoneal seeding | 17 (1.5) | 1 (0.7) | |
| Other |
12 (1.0) | 3 (2.0) | |
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age >65 yr | 1.192 (0.608–2.335) | 0.609 | 1.144 (0.582–2.246) | 0.697 |
| Female sex | 1.032 (0.530–2.006) | 0.927 | 1.024 (0.522–2.011) | 0.945 |
| ASA physical status III–IV | 1.695 (0.657–4.368) | 0.275 | ||
| CEA >5 ng/mL | 1.191 (0.567–2.502) | 0.644 | ||
| Transverse colon | 4.130 (2.055–8.299) | <0.001 | 4.513 (2.226–9.154) | <0.001 |
| T3–T4 category | 5.733 (0.785–41.883) | 0.085 | 4.220 (0.569–31.325) | 0.159 |
| N2 category | 1.985 (1.021–3.860) | 0.043 | 2.044 (1.034–4.042) | 0.040 |
| Adjuvant chemotherapy | 2.146 (0.831–5.539) | 0.114 | ||
| Proximal resection margin <5 cm | 0.381 (0.091–1.586) | 0.185 | ||
| Distal resection margin <5 cm | 1.029 (0.518–2.043) | 0.935 | ||
| Lymphatic invasion | 2.004 (0.997–4.028) | 0.051 | ||
| Venous invasion | 2.122 (1.087–4.145) | 0.028 | ||
| Perineural invasion | 2.570 (1.168–5.658) | 0.019 | ||
Values are presented as mean±standard deviation, number (%), or median (interquartile range). BMI, body mass index; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen
Values are presented as number (%) or mean±standard deviation. Data on lymphatic, venous, and perineural invasion were unavailable for 3 patients in the nontransverse colon cancer group, and perineural invasion data were unavailable for 1 patient in the transverse colon cancer group, due to incomplete pathological records.
Combined systemic and locoregional recurrence was detected in 8 patients in the nontransverse colon cancer group and in 4 patients in the transverse colon cancer group. aPatients could have recurrence at more than one systemic site. bIncluding the ovaries, spleen, small bowel, adrenal gland, ureter, and bone.
Lymphatic, venous, and perineural invasion were excluded from the multivariate analysis to avoid potential multicollinearity in consideration of the limited number of events. HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen.